Sinocare (SHE:300298), through its unit Sino Bio (Hong Kong), signed a distribution agreement with Italian healthcare Menarini Diagnostics, according to a Shenzhen Stock Exchange filing on Tuesday.
A. Menarini Diagnostics will exclusively distribute the Chinese medical device manufacturer's first-generation and second-generation continuous glucose monitoring systems or the iCan CGM System in Europe.
The contract is valid for seven years, but it can be renewed every five years, the disclosure said.
Sinocare's shares jumped less than 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.